Stem cells for intervertebral disc degeneration: evidence, trials and regulatory status
Cell-based intradiscal therapies are being studied for selected lumbar discogenic pain and degeneration, but they remain investigational. No stem-cell product is broadly approved to regenerate a painful intervertebral disc.
The phrase “stem-cell treatment” can refer to very different products: autologous bone-marrow mesenchymal cells, allogeneic cells, nucleus-pulposus-derived cells, cultured cell products, minimally processed aspirates or tissue supplements. These products are not biologically or regulatorily equivalent. A clinic’s marketing term does not identify the actual product, manufacturing controls or level of evidence.
Assessment and decision points
Discogenic pain is difficult to identify because degeneration is common in people without symptoms. Clinical trials usually apply narrow inclusion criteria: chronic axial low back pain, one or a few mildly to moderately degenerated lumbar discs, failure of conservative care, minimum disc height and absence of major instability, stenosis, fracture, infection or neurological emergency. These research criteria should not be converted into broad commercial eligibility.
| Clinical situation | Possible next step | Why it matters |
|---|---|---|
| FDA- or Health-Canada-authorized clinical trial | Investigational access with oversight | Protocol, manufacturing and adverse-event monitoring are reviewed. |
| Commercial injection marketed as a cure | High caution | Approval, product identity and evidence may be unclear. |
| Progressive weakness or cauda equina symptoms | Not a regenerative-treatment scenario | Urgent neurological or surgical assessment takes priority. |
| Disc degeneration without a clear pain source | Eligibility uncertain | An MRI finding alone does not prove a treatment target. |
Management and treatment choices
Research programs typically evaluate a single intradiscal injection followed by standardized monitoring of pain, disability, quality of life, MRI and adverse events. Participation should involve informed consent, regulatory authorization, trial registration and transparent disclosure of alternatives. An investigational injection should not replace guideline-based education, exercise and other appropriate conservative care, nor delay indicated surgery.
Questions before choosing care
What exactly is being offered?
Identify the practitioner, product, procedure or treatment package.
What evidence applies?
Check whether the studies match the condition and intervention.
What are the alternatives?
Compare active care, observation, procedures and surgery when relevant.
What would change the plan?
Define review, stopping and referral criteria.
Cell and tissue products currently being studied
Regenerative-disc research is not based on one standardized “stem-cell injection.” The products differ in cell source, manufacturing, potency testing, dose, carrier, storage and regulatory classification. Results from one product cannot automatically be transferred to another.
| Investigational approach | What it contains | Key uncertainty |
|---|---|---|
| Autologous bone-marrow MSCs | Culture-expanded mesenchymal stromal cells obtained from the participant. | Manufacturing, dose, cost and reproducibility vary. |
| Allogeneic MSCs | Donor-derived cultured cells prepared as a standardized biological product. | Immune effects, durability and responder selection remain under study. |
| Autologous nucleus-pulposus cells | Disc-derived cells collected, expanded and reinjected. | Early-stage trials have small samples and complex manufacturing. |
| Disc-tissue allograft or nucleus-pulposus supplement | Processed donor tissue or particulate material intended to supplement the disc. | It may not contain viable stem cells and should not be marketed as equivalent to cell therapy. |
| Bone-marrow aspirate concentrate | A mixed concentrate containing platelets, blood cells and a small proportion of progenitor cells. | Composition is variable and it is not the same as a purified or cultured stem-cell product. |
How credible disc-regeneration trials are designed
Careful diagnosis
Trials attempt to identify discogenic axial low back pain and exclude dominant radiculopathy, severe stenosis, instability, fracture, infection and other causes.
Randomization and sham control
A sham procedure helps distinguish the biological product from the effects of an invasive procedure, expectation and natural fluctuation.
Standardized manufacturing
Cell identity, viability, sterility, dose and release criteria should be controlled.
Meaningful outcomes
Pain, disability, quality of life, medication use, work and need for surgery matter more than a single MRI feature.
Long-term follow-up
Delayed infection, abnormal tissue growth, immune reactions and durability require years of monitoring.
Transparent reporting
Funding, adverse events, withdrawals, protocol changes and negative findings should be published.
What would count as genuine clinical regeneration?
A therapy would need to show more than temporary pain relief. Strong evidence would demonstrate reproducible improvement compared with a credible control, durable function, acceptable adverse-event rates and a biologically plausible structural effect. Even a favourable MRI signal would not prove that the disc has returned to normal or that future surgery has been prevented.
- Improvement should exceed a clinically meaningful threshold rather than only statistical significance.
- Benefits should persist beyond the short-term placebo and procedure effects.
- Results should be reproduced by independent research groups.
- The exact marketed product should match the product tested in the published trial.
- Manufacturing and sterility should meet regulatory standards.
- Adverse events and treatment failures should be reported completely.
Questions before paying for a regenerative disc procedure
What is the exact product?
Ask for the product name, cell source, processing method, manufacturer, lot controls and whether viable cells are actually present.
What authorization applies?
Request the Health Canada or FDA authorization, investigational-new-drug number or clinical-trial identifier.
Which published trial matches this product?
A study of cultured allogeneic cells does not validate an office-prepared bone-marrow concentrate or Wharton’s jelly product.
Who pays for complications?
Clarify follow-up, emergency care, infection management, adverse-event reporting and financial responsibility.
- Be cautious with guarantees of disc regrowth, permanent pain elimination or avoidance of surgery.
- Be cautious when a clinic uses “FDA registered” or “listed on ClinicalTrials.gov” as if this meant product approval.
- Ask whether the procedure is part of an authorized trial with independent ethics review.
- Request written information about alternatives, including continued rehabilitation and conventional medical care.
- Do not stop indicated treatment or delay urgent neurological assessment because of a regenerative claim.
Frequently asked questions
Are stem cells approved for intervertebral disc disease?
The FDA states that regenerative products are not approved for orthopedic conditions such as disc disease or back pain; Canadian cell therapies also require authorization.
Does a ClinicalTrials.gov listing mean the treatment is approved?
No. Trial registration does not equal market authorization.
Can stem cells regrow a normal disc?
This has not been established in routine clinical care.
What is an intradiscal injection?
A procedure that introduces a product directly into the disc.
Are bone-marrow concentrate and cultured stem cells the same?
No. They differ in composition, processing and regulation.
Can pain improve without MRI regeneration?
Yes.
What are the risks?
Potential risks include infection, inflammatory reaction, nerve injury, product contamination, treatment failure and unknown long-term effects.
Who qualifies for trials?
Eligibility is narrow and defined by each protocol.
Should I pay for treatment outside a trial?
Verify regulatory authorization, exact product identity, evidence, costs, follow-up and adverse-event reporting before considering any intervention.
Does The Spine Page recommend a stem-cell clinic?
No. This page provides evidence and regulatory context only.
Sources consulted
- Health Canada — Risks of unauthorized cell therapies
- Health Canada — Policy Position Paper on Autologous Cell Therapy Products
- FDA — Important patient information about regenerative medicine therapies
- ClinicalTrials.gov — ASCEND VIA Disc NP phase II trial
- ClinicalTrials.gov — Rebonuputemcel phase III trial
- ClinicalTrials.gov — Autologous nucleus-pulposus cells phase I/II trial
- Noriega et al. — Allogeneic mesenchymal cells randomized trial
Last editorial review: July 2026. General educational information only.
Dr. Sylvain Desforges, B.Sc., D.O., N.D., osteopath — The Spine Page
Continue exploring spine health
Use the condition and treatment hubs to compare related guides.
The Spine Page — The best treatments for your spinal problems — www.thespinepage.com